Onconova Therapeutics, Inc. (NASDAQ:ONTX) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET
Company Participants
Bruce Mackle - LifeSci Advisors
Steven Fruchtman - CEO, President & Director
Mark Gelder - Chief Medical Officer
Mark Guerin - CFO & COO
Conference Call Participants
Edouard Mullarky - Guggenheim Securities
Ahu Demir - Ladenburg Thalmann & Co.
Joseph Pantginis - H.C. Wainwright & Co.
Robert LeBoyer - NOBLE Capital Markets
Operator
Ladies and gentlemen, thank you for standing by. Welcome to the Onconova Therapeutics Fourth Quarter and Full Year 2022 Financial Results and Business Update Conference Call. [Operator Instructions].
At this time, I would like to turn the call over to Bruce Mackle of LifeSci Advisors.
Bruce Mackle
Thank you, operator, and welcome, everyone, to Onconova's fourth quarter and full year 2022 financial results and business update conference call. Earlier this afternoon, Onconova issued a press release reporting its financial results and business progress. If you have not seen this press release, it is available in the Investors and Media section of the company's website at onconova.com.
Following my introduction, we will hear from Onconova's President and CEO, Dr. Steve Fruchtman; Chief Medical Officer; Dr. Mark Gelder; and Chief Operating Officer and Chief Financial Officer, Mark Guerin. These prepared remarks will then be followed by a question-and-answer session.
Before we begin, I would like to remind everyone that statements made during this conference call will include forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties that can cause actual results to differ materially. Forward-looking statements speak only as of the date they are made as the underlying facts and circumstances may change. Except as required by law, Onconova disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances.
For more information on forward-looking statements, please review the disclaimer in today's press release and the risk factors in the company's SEC filings.
With that, I will now turn the call over to Onconova's President and CEO, Dr. Steve Fruchtman.
Steven Fruchtman
Thank you, Bruce, and thanks to all who have joined the call today. We are entering a very exciting time for Onconova as our recent progress has us moving toward anticipated milestones that we believe will serve as key value inflection points. I'll begin today by providing the highlights of this progress. Before turning the call over to Dr. Mark Gelder, our Chief Medical Officer, to elaborate further.